trial
as of 2026-07-01Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder
NCTId NCT02055287
at a glance
Phase 1 · Completed
Enrollment 36 (actual)
Sponsored by Luye Pharma Group Ltd.
Primary completion 2014-06
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
36 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2013-03
Primary completion
2014-06
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Luye Pharma Group Ltd.Lead Sponsor
Sites
2 total
Orange, United StatesAustin, United States
Facts & assertions
4 sourced
Enrollment
36
Phase
PHASE1
Primary Completion Date
2014-06
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication